Related references
Note: Only part of the references are listed.UK clinical guideline for the prevention and treatment of osteoporosis
Celia L. Gregson et al.
ARCHIVES OF OSTEOPOROSIS (2022)
Clinical Practice Guideline for Postoperative Rehabilitation in Older Patients With Hip Fractures
Kyunghoon Min et al.
ANNALS OF REHABILITATION MEDICINE-ARM (2021)
Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture
K. Zhu et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Athanasios D. Anastasilakis et al.
JOURNAL OF CLINICAL MEDICINE (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
Dennis M Black et al.
Lancet Diabetes & Endocrinology (2020)
Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures
Zhong Liu et al.
ORTHOPAEDIC SURGERY (2019)
Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates A Meta-analysis
Steven R. Cummings et al.
JAMA INTERNAL MEDICINE (2019)
Bone turnover markers: are they clinically useful?
Richard Eastell et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial
Lee Shepstone et al.
LANCET (2018)
EPIDEMIOLOGY AND POSTOPERATIVE OUTCOMES OF ATYPICAL FEMORAL FRACTURES IN OLDER ADULTS: A SYSTEMATIC REVIEW
K. S. F. Khow et al.
JOURNAL OF NUTRITION HEALTH & AGING (2017)
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
T. Nakamura et al.
OSTEOPOROSIS INTERNATIONAL (2017)
What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review
Suad Aljohani et al.
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2017)
Hip fracture risk and safety with alendronate treatment in the oldest-old
K. F. Axelsson et al.
JOURNAL OF INTERNAL MEDICINE (2017)
The emperor redressed: treating osteoporosis to prevent hip fractures in the oldest old
B. Abrahamsen
JOURNAL OF INTERNAL MEDICINE (2017)
Rethinking the Appraisal and Approval of Drugs for Fracture Prevention
Juan Erviti et al.
FRONTIERS IN PHARMACOLOGY (2017)
Fragility Fractures & Their Impact on Older People
Lidia Sanchez-Riera et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2017)
A systematic review of trends in the selective exclusion of older participant from randomised clinical trials
Miriam Thake et al.
ARCHIVES OF GERONTOLOGY AND GERIATRICS (2017)
A Review of Osteoporosis in the Older Adult
Paloma Alejandro et al.
CLINICS IN GERIATRIC MEDICINE (2017)
Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis
Smita Jha et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Osteoporosis: the emperor has no clothes
T. L. N. Jarvinen et al.
JOURNAL OF INTERNAL MEDICINE (2015)
TOO MUCH MEDICINE Overdiagnosis of bone fragility in the quest to prevent hip fracture
Teppo L. N. Jarvinen et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
TOO MUCH MEDICINE Overdiagnosis of bone fragility in the quest to prevent hip fracture
Teppo L. N. Jarvinen et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures An Updated Systematic Review
Carolyn J. Crandall et al.
ANNALS OF INTERNAL MEDICINE (2014)
Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case–control study
Juan Erviti et al.
BMJ Open (2013)
Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
Steven Boonen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk
S. Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older
Steven Boonen et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2010)
The evidence for antiresorptive osteoporosis treatment in the elderly and old
M. V. Maraldo et al.
EUROPEAN GERIATRIC MEDICINE (2010)
Effect of alendronate in elderly patients after low trauma hip fracture repair
D. Cecilia et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: Results of a double-blind, placebo-controlled randomized study
Eugene V. McCloskey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures
MC Hochberg et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study
JYY Leung et al.
BONE (2005)
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old
S Boonen et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2004)
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis:: Results of a double-blind, placebo-controlled 3-year study
E McCloskey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy -: A randomized controlled trial
BH Ascott-Evans et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis
LO Chailurkit et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2003)
Daily oral pamidronate in women and men with osteoporosis: A 3-year randomized placebo-controlled clinical trial with a 2-year open extension
C Brumsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities - A randomized, double-blind, placebo-controlled trial
SL Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2002)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
